Literature DB >> 9486263

Effects of aminooxyacetate on glutamate compartmentation and TCA cycle kinetics in rat hearts.

A D Sherry1, P Zhao, A J Wiethoff, F M Jeffrey, C R Malloy.   

Abstract

The nonspecific transaminase inhibitor aminooxyacetate (AOA) has multiple influences on the dynamics of 13C appearance in glutamate in rat hearts as measured by 13C nuclear magnetic resonance (NMR) without altering O2 consumption or tricarboxylic acid (TCA) cycle flux. These include the following: 1) a reduced rate of 13C enrichment at glutamate C3 and C4; 2) a near coalescence of the C3 and C4 fractional enrichment curves; 3) a dramatic alteration in the time-dependent evolution of the glutamate C4 multiplets, C4S and C4D34; and 4) a decrease in the NMR visibility of glutamate. A fit of the 13C fractional enrichment curves of glutamate C4 and C3 in the absence of inhibitor to a kinetic model of the TCA cycle gave values for transaminase flux of 7.5 mumol.min-1.g dry wt-1 and TCA cycle flux of 7.5 mumol.min-1.g dry wt-1, thereby confirming reports by others that the kinetics of 13C enrichment of glutamate C3 and C4 in heart tissue is significantly affected by flux through reactions other than TCA cycle. The 13C fractional enrichment data collected in the presence of 0.5 mM AOA could not be fitted using this same kinetic model. However, kinetic simulations demonstrated that the time-dependent changes in C4S and C4D34 are only consistent with a 10-fold reduction in the size of intermediate pools undergoing rapid turnover in the TCA cycle. We conclude that inhibition of glutamic-oxalacetic transaminase by AOA effectively reduces the size of the alpha-ketoglutarate pool in rapid exchange with the TCA cycle. Our data indicate that changes in glutamate multiplet areas in the 13C NMR spectra of heart (as demonstrated by glutamate C4S and C4D34) are more sensitive to alterations in metabolic pool sizes in exchange with the TCA cycle than are measurements of 13C fractional enrichment at glutamate C3 and C4.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9486263     DOI: 10.1152/ajpheart.1998.274.2.H591

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

Review 1.  Cystathionine-β-Synthase: Molecular Regulation and Pharmacological Inhibition.

Authors:  Karim Zuhra; Fiona Augsburger; Tomas Majtan; Csaba Szabo
Journal:  Biomolecules       Date:  2020-04-30

2.  Transamination is required for {alpha}-ketoisocaproate but not leucine to stimulate insulin secretion.

Authors:  Yingsheng Zhou; Thomas L Jetton; Stephanie Goshorn; Christopher J Lynch; Pengxiang She
Journal:  J Biol Chem       Date:  2010-08-24       Impact factor: 5.157

Review 3.  International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors.

Authors:  Csaba Szabo; Andreas Papapetropoulos
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

Review 4.  Metabolic Modeling of Dynamic (13)C NMR Isotopomer Data in the Brain In Vivo: Fast Screening of Metabolic Models Using Automated Generation of Differential Equations.

Authors:  Brice Tiret; Alexander A Shestov; Julien Valette; Pierre-Gilles Henry
Journal:  Neurochem Res       Date:  2015-11-09       Impact factor: 3.996

5.  A metabolic model of the mitochondrion and its use in modelling diseases of the tricarboxylic acid cycle.

Authors:  Anthony C Smith; Alan J Robinson
Journal:  BMC Syst Biol       Date:  2011-06-29

Review 6.  13C-MR spectroscopy--how and why?

Authors:  U K Decking
Journal:  MAGMA       Date:  1998-09       Impact factor: 2.533

7.  Multi-Target Analysis and Design of Mitochondrial Metabolism.

Authors:  Claudio Angione; Jole Costanza; Giovanni Carapezza; Pietro Lió; Giuseppe Nicosia
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

8.  Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer.

Authors:  Nadiya Druzhyna; Bartosz Szczesny; Gabor Olah; Katalin Módis; Antonia Asimakopoulou; Athanasia Pavlidou; Petra Szoleczky; Domokos Gerö; Kazunori Yanagi; Gabor Törö; Isabel López-García; Vassilios Myrianthopoulos; Emmanuel Mikros; John R Zatarain; Celia Chao; Andreas Papapetropoulos; Mark R Hellmich; Csaba Szabo
Journal:  Pharmacol Res       Date:  2016-08-10       Impact factor: 7.658

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.